Risk of Dependence with Eszopiclone (Lunesta)
Eszopiclone carries a real but relatively low risk of dependence and withdrawal symptoms, particularly when used long-term at therapeutic doses, though this risk is substantially lower than with traditional benzodiazepines. The drug is classified as a Schedule IV controlled substance by the FDA due to its potential for abuse and dependence 1.
Evidence from Clinical Guidelines and FDA Labeling
The American College of Physicians guidelines acknowledge that "use of certain medications for insomnia may lead to tolerance and dependence" 2. However, the evidence quality for long-term harms was rated as insufficient or low strength in randomized trials 2.
The FDA drug label for Lunesta explicitly warns that it "can be abused or lead to dependence" and advises keeping it in a safe place to prevent misuse 1. Following abrupt discontinuation of sedative-hypnotics like eszopiclone, signs and symptoms similar to withdrawal from other CNS-depressant drugs have been reported 1.
Quantifying the Risk
Clinical Trial Data
Research evidence provides more specific risk estimates:
- In a 24-week study of eszopiclone 2 mg followed by abrupt discontinuation, only 10.5% (8 of 76 patients) developed clinically relevant withdrawal symptoms 3
- No clinically significant evidence of pharmacological tolerance, rebound insomnia, or dependence was observed in trials up to 12 months duration 4
- One study showed sustained beneficial effects for up to 12 months with no occurrence of tolerance 5
Withdrawal Symptoms When They Occur
When withdrawal symptoms do develop, they may include 1:
- Anxiety
- Abnormal dreams
- Hyperesthesia (increased sensitivity to stimuli)
- Nausea and upset stomach
- In one case report of zopiclone (the racemic mixture containing eszopiclone): palpitations, sweating, irritability, hallucinations, and impulsive behavior 6
Rebound Insomnia
Rebound insomnia appears minimal with eszopiclone. Meta-analysis showed no significant changes in sleep onset latency or wake time after sleep onset during the first three nights following discontinuation 7. However, one study did report rebound insomnia following withdrawal of 2 mg doses in non-elderly subjects 5.
Risk Factors for Dependence
The strongest predictor of withdrawal symptoms is poor medication compliance and problematic use patterns during treatment 3. Multiple logistic regression analysis identified that dependence behaviors and poor compliance (measured by Bendep-SRQ SV subscale) were significantly correlated with withdrawal symptoms (odds ratio 1.650,95% CI 1.105-2.464, p=0.014) 3.
Abuse Potential
Unpublished data cited in research show that eszopiclone at supratherapeutic doses (6 and 12 mg) produces euphoria effects similar to diazepam 20 mg in individuals with benzodiazepine addiction history 5. This indicates abuse potential exists, particularly in those with substance use history.
Clinical Implications
Who Is at Higher Risk:
- Patients with history of alcohol or drug abuse/dependence 1
- Those taking doses above recommended levels
- Patients with poor medication compliance patterns
- Those using eszopiclone with alcohol or other CNS depressants 1
Mitigation Strategies:
- Screen for substance abuse history before prescribing 1
- Provide clear guidance on proper compliance to reduce withdrawal risk 3
- Use the lowest effective dose - FDA emphasizes this is particularly important in elderly patients 1
- Avoid combining with alcohol or other CNS depressants, which increases risk of complex behaviors and dependence 1
- Consider gradual tapering rather than abrupt discontinuation, though specific tapering protocols were not established in the evidence
Important Caveat:
The 2016 American College of Physicians guideline notes that observational studies must be interpreted with caution due to possible unmeasured confounders 2. Most trial participants were carefully selected, so real-world dependence rates in typical primary care populations may differ 2.
Comparative Context
While eszopiclone has dependence potential, it appears to have more selectivity for certain GABA(A) receptor subunits compared to benzodiazepines 5, theoretically conferring a more favorable safety profile. The evidence suggests the dependence risk is present but manageable when the medication is used as prescribed at recommended doses for appropriate durations.